MedTrace Logo

The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia

NCT05035589 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-04-11

No results posted yet for this study

Summary

This study aims to establish whether tocilizumab has any significant effect on procalcitonin levels on patients diagnosed with COVID-19 pneumonia requiring intensive care admission. The effects on other biochemical and clinical markers are also considered.

Conditions

Interventions

DRUG

Tocilizumab

Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg

Sponsors & Collaborators

  • Mater Dei Hospital, Malta

    collaborator OTHER

  • Sciberras, Stephen M.D.

    lead INDIV

Eligibility

Min Age
16 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2021-10-20
Completion
2021-11-20

Countries

  • Malta

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05035589 on ClinicalTrials.gov